Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Positron Emission Tomography Assessment of the Central Nervous System Effects of Eszopiclone and Zolpidem

Next Previous
Trial Profile

Positron Emission Tomography Assessment of the Central Nervous System Effects of Eszopiclone and Zolpidem

Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 11 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eszopiclone (Primary) ; Zolpidem (Primary)
  • Indications Depressive disorders; Generalised anxiety disorder; Insomnia
  • Focus Pharmacokinetics

Most Recent Events

  • 13 Jan 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
  • 05 Aug 2009 Planned initiation date changed from 1 Jan 2009 to 1 Sep 2009 as reported by ClinicalTrials.gov.
  • 05 Aug 2009 Planned end date changed from 1 Mar 2009 to 1 Dec 2009 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top